Open access
Oct 2026
Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study.
BACKGROUND MEK inhibition has demonstrated activity in pediatric low-grade gliomas (pLGGs) driven by BRAF rearrangements, but data on trametinib remain limited, regarding efficacy, short and long-term toxicities. METHODS We conducted a retrospective multicenter study of patients with BRAF-rearranged non NF1 pLGGs rec...
Céline Khouri, Amandine Bibollet, Y. Bouchoucha et al.
· European Journal of Cancer · 0 citations